DEFIBROTIDE SHOWS EFFICACY IN THE PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY ON 237 PATIENTS.
暂无分享,去创建一个
C. Dantin | M. Ansari | F. Giannotti | Y. Chalandon | S. Masouridi-Levrat | F. Simonetta | Y. Beauverd | Fanette Bernard | C. Stephan | A. Mamez | S. Morin | Elif Mahne | Maria Mappoura | Carmen de Ramon Ortiz | C. D. R. Ortiz
[1] M. Cairo,et al. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation , 2020, British journal of haematology.
[2] P. Richardson,et al. Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced intensity allogeneic hematopoietic cell transplantation. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] P. Richardson,et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group , 2019, Bone Marrow Transplantation.
[4] M. Pasquini,et al. Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] P. Richardson,et al. Defibrotide for the treatment of hepatic veno‐occlusive disease/sinusoidal obstruction syndrome following nontransplant‐associated chemotherapy: Final results from a post hoc analysis of data from an expanded‐access program , 2018, Pediatric blood & cancer.
[6] A. Schulz,et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation , 2017, Bone Marrow Transplantation.
[7] P. Richardson,et al. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] M. Abecassis,et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation , 2016, Bone Marrow Transplantation.
[9] R. D'Agostino,et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. , 2016, Blood.
[10] M. Abecassis,et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.
[11] G. Keating. Defibrotide: A Review of Its Use in Severe Hepatic Veno-Occlusive Disease Following Haematopoietic Stem Cell Transplantation , 2014, Clinical Drug Investigation.
[12] P. Richardson,et al. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation , 2012, Expert review of hematology.
[13] A. Schulz,et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.
[14] M. Díaz-Ricart,et al. Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.
[15] M. Díaz-Ricart,et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] Allen R. Chen,et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] B. Chapuis,et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] D. Perry,et al. Veno-occlusive disease: cytokines, genetics, and haemostasis. , 2003, Blood reviews.
[19] Allen R. Chen,et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. , 2002, Blood.
[20] A. Mcmillan,et al. Hepatic Venoocclusive Disease in Blood and Bone Marrow Transplantation in Children and Young Adults: Incidence, Risk Factors, and Outcome in a Cohort of 241 Patients , 2002, Journal of pediatric hematology/oncology.
[21] M. Remberger,et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. , 2002, Blood.
[22] Ha Yeon Lee,et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.
[23] G. McDonald,et al. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). , 2002, Seminars in liver disease.
[24] R. Miralbell,et al. Total body irradiation before allogeneic bone marrow transplantation: is more dose better? , 2001, International journal of radiation oncology, biology, physics.
[25] T. Barbui,et al. Defibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study , 2000, British journal of haematology.
[26] E. Carreras. Veno‐occlusive disease of the liver after hemopoietic cell transplantation , 2000, European journal of haematology.
[27] R S McCuskey,et al. Characterization of a reproducible rat model of hepatic veno‐occlusive disease , 1999, Hepatology.
[28] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[29] D. Neuberg,et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.
[30] W. Wilmanns,et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. , 1997, Blood.
[31] N. Kaplowitz,et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venoocclusive disease , 1996 .
[32] S. Bearman,et al. The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.
[33] G. McDonald,et al. Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms , 1994, Hepatology.
[34] G. Anderson,et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Grañena,et al. Hepatic veno-occlusive disease after bone marrow transplant. , 1993, Blood reviews.
[36] G. McDonald,et al. Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.
[37] P. Brousset,et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. , 1992, Blood.
[38] E. Gluckman,et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. , 1991, Thrombosis research.
[39] L. Grochow,et al. VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.
[40] A. Gown,et al. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. , 1987, The American journal of pathology.
[41] B. Rollins. Hepatic veno-occlusive disease. , 1986, The American journal of medicine.
[42] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[43] E. Horwitz,et al. Anicteric veno-occlusive disease after hematopoietic stem cell transplantation in children , 2016, Bone Marrow Transplantation.
[44] M. Labopin,et al. Comparison of RIC-alloHCT and autoHCT for > 55 years old patients with acute lymphoblastic leukemia: an analysis from Acute Leukemia Working Party of the EBMT , 2015 .
[45] P. Ljungman,et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. , 1998, Blood.
[46] Pankaj Sharma,et al. Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors , 1984, Hepatology.